DEF: Haemonetics Sets July 24, 2026 Annual Meeting

Haemonetics Corporation announced its 2026 Annual Meeting of Shareholders will be held on July 24, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.

Summary

• Haemonetics Corporation is holding its 2026 Annual Meeting of Shareholders on Friday, July 24, 2026, at 8:00 AM Eastern Time.
• The meeting will take place at the Company's headquarters at 125 Summer Street, Boston, Massachusetts.
• Key agenda items include the election of eight director nominees, an advisory vote on executive compensation, ratification of Ernst & Young LLP as the independent auditor, and approval of amendments to the 2019 Long-Term Incentive Compensation Plan and the 2007 Employee Stock Purchase Plan.
• Shareholders of record as of May 22, 2026, are eligible to vote.
• Proxy materials are being furnished online, with a mailing date of June 10, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting strong operational execution and strategic progress in fiscal 2026, despite some market headwinds and a share price decline. The company's commitment to innovation and shareholder value is evident, though the need for additional equity under the incentive plan warrants attention.

Positives

• Haemonetics reports strong fiscal 2026 performance, meeting or exceeding nearly all financial targets despite prior-year portfolio transitions.
• Plasma and TEG product lines drove organic growth through sustained share gains and innovation.
• Key strategic initiatives were completed, including FDA clearance for NexSys PCS with Persona PLUS technology and expanded labeling for the VASCADE MVP XL venous vascular closure system.
• Acquisition of Vivasure Medical in Vascular Closure strengthens the portfolio.
• Leadership team strengthened with the addition of Frank Chan as COO and promotion of Roy Galvin to CCO.
• Successful completion of a four-year long-range plan, building a more diversified and sustainable business.
• Shareholder outreach efforts were conducted, with generally positive feedback on executive compensation.
• High approval rate (approximately 98.6%) for the advisory say-on-pay vote in the previous year.
• The company maintains strong governance and pay practices, including share ownership guidelines and clawback policies.
• The Board recommends a FOR vote on all proposed items, indicating confidence in the company's direction and governance.

Negatives

• Revenue growth faced headwinds from prior-year portfolio transitions, including the sale of the Whole Blood product line and wind-down of the CSL Plasma U.S. supply agreement, which together represented approximately $153 million of nonrecurring fiscal 2025 revenue.
• Interventional Technologies faced near-term challenges due to competitive dynamics and evolving electrophysiology trends.
• Despite financial and strategic achievements, the company's share price performance declined in fiscal 2026 due to external market challenges and macroeconomic uncertainties.
• The proposed amendment to the 2019 Long-Term Incentive Compensation Plan seeks an additional 4,680,000 shares, which would increase the equity overhang to approximately 14.69% if approved.

Risks

• Factors that may cause actual results to differ materially from forward-looking statements include those detailed in the Company's most recent Annual Report on Form 10-K under 'Cautionary Statement Regarding Forward-Looking Information' and 'Risk Factors'.
• The company acknowledges macroeconomic uncertainties that could materially impact financial results.
• The company's share price performance declined in fiscal 2026 due to external market challenges and macroeconomic uncertainties.

Future Outlook

Looking ahead to fiscal 2027, the company remains focused on creating long-term value for shareholders through expanded market share, continued innovation, and sustained growth across its core products.

Management Comments

• Haemonetics delivered strong fiscal 2026 performance, reflecting disciplined execution, strategic innovation and strengthened leadership.
• We met or exceeded nearly all of our total company financial targets for fiscal year 2026 despite revenue growth headwinds from prior-year portfolio transitions.
• Our Plasma and TEG product lines drove fiscal 2026 organic growth through sustained share gains, innovation-based pricing and durable end-market demand, demonstrating the strength and resilience of these core products and our increasingly productive operating model.
• In Interventional Technologies, we addressed near-term challenges driven by competitive dynamics and evolving electrophysiology trends through targeted commercial measures and operational improvements, positioning the portfolio for a return to growth in future periods.
• The addition of Frank Chan as Chief Operating Officer and the promotion of Roy Galvin to Chief Commercial Officer further strengthened our leadership team and streamlined our commercial and operational capabilities.
• Haemonetics fiscal 2026 year-end also marked the successful completion of our four-year long-range plan, during which we built a more diversified, sustainable and durable business and delivered strong results against ambitious multi-year goals.
• Looking ahead to fiscal 2027, we remain focused on creating long-term value for shareholders through expanded market share, continued innovation and sustained growth across our core products.

Industry Context

StockSavvy.ai notes that Haemonetics' performance in fiscal 2026, particularly in its Plasma and TEG product lines, highlights the company's ability to drive organic growth through market share gains and innovation, even amidst broader industry challenges. The strategic acquisitions and product clearances mentioned indicate a proactive approach to strengthening its market position in key healthcare technology segments.

Comparison to Industry Standards

• The company's peer group for setting fiscal 2026 compensation includes companies like Avanos Medical, Inc., Bruker Corporation, Insulet Corporation, and Merit Medical Systems, Inc., among others.
• Haemonetics' revenue ($1,361 million) and market capitalization ($4,393 million) placed it around the 40th percentile of its peer group.
• The company's burn rate for equity awards averaged approximately 1.1% over the last three fiscal years, which is considered conservative compared to industry standards.
• The proposed increase in shares available under the 2019 Long-Term Incentive Compensation Plan would result in an overhang of approximately 14.69%, which the company believes is measured and appropriate given its conservative burn rate and commitment to aligning pay with long-term shareholder value.

Management Changes

Corporate Governance

Related Party Transactions

• The Board has a policy for approving transactions with related persons, reviewed by the Audit Committee, to ensure terms are no less favorable than with unrelated third parties and that the transaction is in the Company's best interest.

Stakeholder Impact

• Shareholders are encouraged to vote to support the company's strategic direction and governance.
• Employees and key advisors will continue to be incentivized through equity awards under the proposed amended long-term incentive plan.
• Employees will have continued opportunity to purchase company stock through the amended employee stock purchase plan.

Next Steps

• Shareholders are encouraged to vote their shares for the proposals presented at the Annual Meeting.
• The company will continue to focus on creating long-term value through expanded market share, innovation, and sustained growth in fiscal 2027.

Key Dates

Recommendation

While Haemonetics demonstrated strong operational performance and strategic progress in fiscal 2026, the decline in share price due to market conditions and the need for additional equity issuance under incentive plans suggest a cautious approach. The company is well-positioned in its core markets, but the near-term share price performance and potential dilution warrant a 'hold' recommendation until market conditions improve and the impact of new initiatives is fully realized.

Keywords

Haemonetics, Proxy Statement, Annual Meeting, Shareholders, Director Election, Executive Compensation, Auditor Ratification, Incentive Plan, Stock Purchase Plan, Corporate Governance